Premiere Date: March 20, 2015
Expiration Date: March 20, 2016
This activity offers CE credits for:
1. Physicians (CME)
To understand the obstacles standing in the way of smoking cessation in patients with mental illness and the strategies that can help patients abstain from smoking.
At the end of this CE activity, participants should be able to:
1. Understand the obstacles that stand in the way of smoking cessation in patients with mental illness
2. Describe the recommendations of the US public Health Service and the American Psychiatric Association to help patients quit smoking
3. Describe the evidence base for treating tobacco addiction in smokers with co-occurring mental illness or addictive disorders
This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.
CME Credit (Physicians): This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for 1.5 AMA PRA Category 1 Credit™.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process.
The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Stephen E. Hall, MD, has no disclosures to report.
Judith J. Prochaska, PhD, MPH, reports that she has received an independent investigator award from Pfizer and is an ad hoc member of their advisory board and grant reviewer for their grant program. She has also served as an expert witness against the tobacco companies in several lawsuits for which she has received fees.
A. Eden Evins, MD, MPH (peer/content reviewer), has no disclosures to report.
Applicable Psychiatric Times staff and CME Outfitters staff have no disclosures to report.
UNLABELED USE DISCLOSURE
Faculty of this CME/CE activity may include discussion of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767)
Dr Hall is Clinical Professor of Psychiatry at the University of California, San Francisco; when this article was written, he was Director of Intensive Services at the Langley Porter Psychiatric Institute. He is currently Associate Director for Development in the department of psychiatry at The Jewish Home of San Francisco. Dr Prochaska is Associate Professor of Medicine with the Stanford Prevention Research Center in the department of medicine at Stanford University, Stanford, Calif.
1. Centers for Disease Control and Prevention. Smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 2000-2004. MMWR Morb Mortal Wkly Rep. 2008;57:1226-1228.
2. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284:2606-2610.
3. Hitsman B, Moss TG, Montoya ID, George TP. Treatment of tobacco dependence in mental health and addictive disorders. Can J Psychiatry. 2009;54:368-378.
4. Grant BF, Hasin DS, Chou SP, et al. Nicotine dependence and psychiatric disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:1107-1115.
5. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update: A US Public Health Service report. Am J Prev Med. 2008;35:158-176.
6. Prochaska JJ, Fromont SC, Louie AK, et al. Training in tobacco treatments in psychiatry: a national survey of psychiatry residency training directors. Acad Psychiatry. 2006;30:372-378.
7. Prochaska JJ, Hall SE, Delucchi K, Hall SM. Efficacy of initiating tobacco dependence treatment in inpatient psychiatry: a randomized controlled trial. Am J Public Health. 2014;104:1557-1565.
8. Barnett PG, Wong W, Jeffers A, et al. Cost-effectiveness of smoking cessation treatment initiated during psychiatric hospitalization. J Clin Psychiatry. In press.
9. Hall SM, Prochaska JJ. Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. Annu Rev Clin Psychol. 2009;5:409-431.
10. Williams JM, Steinberg ML, Griffiths KG, Cooperman N. Smokers with behavioral health comorbidity should be designated a tobacco use disparity group. Am J Public Health. 2013;103:1549-1555.
11. McFall M, Saxon AJ, Malte CA, et al; CSP 519 Study Team. Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. JAMA. 2010;304:2485-2493.
12. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. 2nd ed. New York: Guilford Press; 2002.
13. Carpenter MJ, Hughes JR, Solomon LJ, Callas PW. Both smoking reduction with nicotine replacement therapy and motivational advice increase future cessation among smokers unmotivated to quit. J Consult Clin Psychol. 2004;72:371-381.
14. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Library. May 31, 2013. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009329.pub2/pdf. Accessed January 29, 2015.
15. Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry. 2013;170:1460-1467.
16. Practice guidelines for the treatment of patients with nicotine dependence. American Psychiatric Association. Am J Psychiatry. 1996;153(10 suppl):1-31.
17. Klungsøyr O, Nygård JF, Sørensen T, Sandanger I. Cigarette smoking and incidence of first depressive episode: an 11-year, population-based follow-up study. Am J Epidemiol. 2006;163:421-432.
18. Gierisch JM, Bastian LA, Calhoun PS, et al. Smoking cessation interventions for patients with depression: a systematic review and meta-analysis. J Gen Intern Med. 2011;27:351-360.
19. Breslau N, Schultz LR, Johnson EO, et al. Smoking and the risk of suicidal behavior: a prospective study of a community sample. Arch Gen Psychiatry. 2005;62:328-334.
20. Oquendo MA, Galfalvy H, Russo S, et al. Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am J Psychiatry. 2004;161:1433-1441.
21. Glassman AH, Covey LS, Stetner F, Rivelli S. Smoking cessation and the course of major depression: a follow-up study. Lancet. 2001;357:1929-1932.
22. Kahler CW, Brown RA, Ramsey SE, et al. Negative mood, depressive symptoms, and major depression after smoking cessation treatment in smokers with a history of major depressive disorder. J Abnorm Psychol. 2002;111:670-675.
23. Tsoh JY, Humfleet GL, Muñoz RF, et al. Development of major depression after treatment for smoking cessation [published correction appears in Am J Psychiatry. 2000;157:1359]. Am J Psychiatry. 2000;157: 368-374.
24. Prochaska JJ, Hall SM, Tsoh JY, et al. Treating tobacco dependence in clinically depressed smokers: effect of smoking cessation on mental health functioning. Am J Public Health. 2008;98:446-448.
25. Hall SM, Tsoh JY, Prochaska JJ, et al. Treatment for cigarette smoking among depressed mental health outpatients: a randomized clinical trial. Am J Public Health. 2006;96:1808-1814.
26. Taylor G, McNeill A, Girling A, et al. Change in mental health after smoking cessation: systematic review and meta-analysis [published correction appears in BMJ. 2014;348:g2216]. BMJ. 2014;348:g1151.
27. Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial [published correction appears in Ann Intern Med. 2013;159:576]. Ann Intern Med. 2013;159:390-400.
28. Meyer TE, Taylor LG, Xie S, et al. Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. Addiction. 2013;108:203-210.
29. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3:A42.
30. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25:218-225.
31. Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007;27:380-386.
32. George TP, Vessicchio JC, Sacco KA, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry. 2008;63:1092-1096.
33. Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder [published correction appears in J Clin Psychiatry. 2012;73:1035]. J Clin Psychiatry. 2012;73:654-660.
34. Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder. a randomized clinical trial. JAMA. 2014;311:145-154.
35. Kelly DL, Raley HG, Lo S, et al. Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia. Schizophr Bull. 2012;38:543-551.
36. Prochaska JJ. Failure to treat tobacco use in mental health and addiction treatment settings: a form of harm reduction? Drug Alcohol Depend. 2010;110:177-182.
37. Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol. 2004;72:1144-1156.
38. Hall SM. Nicotine interventions with comorbid populations. Am J Prev Med. 2007;33(6 suppl):S406-S413.